OnKure Therapeutics, Inc. Price & Performance (OKUR)

President Trump has signed a sweeping executive order aimed at reducing prescription drug costs, signaling a renewed push for lower prices and increased transparency. The order directs federal agencies to explore expanded drug importation, pharmacy benefit manager reforms, and changes to Medicare drug negotiations, but immediate regulatory changes will require further action.12

Recent corporate actions have led to several reverse stock splits, delistings, and cash mergers in the biotech sector. SUNation Energy, LQR House, and Hepion Pharmaceuticals executed reverse splits, while companies like Enzo Biochem and Syra Health were delisted to OTC markets, reflecting ongoing volatility and consolidation in the industry.34

Several high-value transactions are pending, including Capital Power’s $2.2 billion acquisition of Hummel and Rolling Hills assets and Dotmatics’ $5.1 billion sale to Siemens. These deals highlight continued consolidation and strategic repositioning in the power generation and pharmaceutical technology markets this month.56